Published • loading... • Updated
Misinformation, hesitancy could blunt impact of new cancer vaccines
Researchers say misinformation and rising vaccine hesitancy could reduce enrollment and limit the public-health impact of new cancer vaccines.
- Chase Johnson, a breast cancer survivor from Cary, North Carolina, is participating in a clinical trial at the Cleveland Clinic testing a new vaccine designed to train the immune system to destroy cancer cells.
- Rising vaccine hesitancy, fueled in part by the Trump administration, could blunt the impact of these emerging treatments, researchers warn, risking adoption of tools that could transform cancer care.
- Health and Human Services Secretary Robert F. Kennedy Jr. has dismissed vaccine advisory panels and challenged manufacturers, actions critics say contribute to a climate of distrust complicating public confidence.
- Misinformation spread by some lawmakers has already reduced uptake of other vaccines, and experts fear a similar dynamic with breast cancer treatments, though evidence-based corrections can help combat false claims.
- Despite broader uncertainty, patients like Johnson find hope in the trial's potential to prevent recurrence. "As a cancer patient, these are life-saving tools that are helping us," Johnson said.
Insights by Ground AI
31 Articles
31 Articles
Hanford Sentinel+30 Reposted by 30 other sources
Misinformation, hesitancy could blunt impact of new cancer vaccines
Nearly five years ago, Chase Johnson was cured of breast cancer — but not of the profound anxiety that it would return. When Johnson was originally diagnosed in 2021, the resident of Cary, North Carolina, was only 31
Coverage Details
Total News Sources31
Leaning Left7Leaning Right1Center23Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 23%
C 74%
Factuality
To view factuality data please Upgrade to Premium
